HISHOH Biopharma
Challenge for an “Allergy-Free World”
Our Technology
HISHOH Biopharma's novel immunostimulant will maximize the potential of allergen immunotherapy and realize an allergy-free world.
TECH1
HSO-001
HSO-001 synergistically lowered antibody levels, a measure of efficacy against hay fever. Based on these results, HSO-001 is expected to produce faster and longer-lasting effects.
TECH 2
Sublingual immunotherapy
AIT is considered the only effective curative therapy for IgE-mediated type I allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis.
NEWS
- 役員人事および取締役会設置会社への移行に関するお知らせ
- HISHOH Biopharma 新取締役就任のお知らせ
- HISHOH Biopharma was introduced on the LINK-J website.
- Nikkei Biotech published an article about our company
- Execution of a license agreement for a substance with immunostimulatory properties and implementation of a third-party allocation of new shares in the seed round
Team
CEO
Chief Executive Officer
Joji Hayashida, Ph.D., MBA
Dr. Hayashida earned his Ph.D. from the University of Chicago and conducted cancer research at Memorial Sloan-Kettering Cancer Center from 2009. After returning to Japan in 2011, he joined Astellas Pharma, contributing to the development of the AML drug XOSPATA and managing manufacturing and operations. From 2016, he worked in corporate strategy, supporting budgeting, FP&A, regenerative medicine, quality assurance, and investment evaluations. In 2019, he joined Cellusion as CFO, later serving as COO and Executive VP until 2025, overseeing strategy, fundraising, and business development. He then founded Acmex Partners to support drug discovery startups.
取締役会長
Chief Science Officer
Naoki Sakurai, Ph.D.
Naoki Sakurai joined HISHOH Biopharma in May, 2021. He has a demonstrated executive history and an extensive R&D background in the pharmaceutical industry with over 30 years of managerial experience in both Japan and the USA. Previously he served as President & CEO of Tanabe Research Laboratories USA where he progressed multiple biologics projects into clinical and preclinical stages. Before that, he worked with Mitsubishi Tanabe Pharma responsible for diverse research functions as well as in-licensing and open-innovation alliances with external organizations.
Dr. Sakurai received his B.S., M.S., and Ph.D. from Kyoto University.
Graduated from Kyoto University (B.A., M.A., Ph.D.); joined the Company in May 2021
取締役
Chief Business Development Officer
Toru Seo, Ph.D., MBA
After earning a PhD from Wake Forest University School of Medicine in the United States, Toru Seo engaged in education as an associate professor of pediatrics at Columbia University School of Medicine. Since 2006, he has been engaged in R & D and business development at GSK, Merck, and Taisho Pharmaceutical. Since 2015, he has been the General Manager of Japan for External Science & Innovation and the General Manager of Asia for Worldwide Research & Development at Pfizer Inc. In addition, while being involved in venture company support and ecosystem construction as an angel investor and parallel entrepreneur, he also works as a consultant and bio-venture advisor for domestic and overseas companies.
Partners
Mitsubishi UFJ Capital Co.
DBJ Capital Corporation
Daiichi Sankyo Company, Limited